BioCentury
ARTICLE | Company News

MaxCyte, JHU partner for preclinical CARs

April 22, 2015 2:19 AM UTC

MaxCyte Inc. (Gaithersburg, Md.) partnered with The Johns Hopkins University (Baltimore, Md.) to develop chimeric antigen receptor (CAR) T cell therapies to treat solid tumors based on MaxCyte's mRNA technology that results in transient expression of the CAR molecule, which MaxCyte hopes will lead to an improved safety profile.

The first program will be a mesothelin-targeted CAR, for which MaxCyte expects to submit an IND next year. Other preclinical targets and financial terms are undisclosed. ...